ICIs mainly include CTLA-4 inhibitors and PD-1/PD-L1 inhibitors, which mainly used in the treatment of melanoma, Hodgkin’s lymphoma and non-small cell lung cancer (NSCLC). Here, CTLA4 is linked to non-small cell lung carcinoma.